Drug Profile
Tocilizumab biosimilar - PanPharmaceuticals USA
Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator PanPharmaceuticals USA
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Rheumatoid arthritis
Most Recent Events
- 17 Jun 2015 PanPharmaceuticals USA has ceased its operations
- 16 Jun 2015 Discontinued for Giant lymph node hyperplasia in USA (unspecified route)
- 16 Jun 2015 Discontinued for Juvenile rheumatoid arthritis in USA (unspecified route)